DKK1,577.50
0.19% today
Copenhagen, Aug 26, 04:59 pm CET
ISIN
DK0010272202
Symbol
GMAB

Genmab A/S Stock price

DKK1,577.50
+80.00 5.34% 1M
-40.50 2.50% 6M
+85.00 5.70% YTD
-256.00 13.96% 1Y
-1,106.50 41.23% 3Y
-797.50 33.58% 5Y
+1,017.00 181.45% 10Y
+1,471.50 1,388.21% 20Y
Copenhagen, Closing price Tue, Aug 26 2025
+3.00 0.19%
ISIN
DK0010272202
Symbol
GMAB
Industry

Key metrics

Basic
Market capitalization
DKK96.6b
Enterprise Value
DKK93.5b
Net debt
positive
Cash
DKK3.2b
Shares outstanding
63.3m
Valuation (TTM | estimate)
P/E
88.8 | 98.7
P/S
29.9 | 26.3
EV/Sales
28.9 | 25.5
EV/FCF
83.1
P/B
18.2
Financial Health
Equity Ratio
80.1%
Return on Equity
22.3%
ROCE
17.9%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
DKK3.2b | DKK3.7b
EBITDA
DKK1.1b | DKK8.7b
EBIT
DKK1.0b | DKK7.8b
Net Income
DKK1.1b | DKK1.0b
Free Cash Flow
DKK1.1b
Growth (TTM | estimate)
Revenue
25.3% | 17.4%
EBITDA
32.4% | 710.8%
EBIT
26.9% | 663.1%
Net Income
43.5% | -11.2%
Free Cash Flow
44.2%
Margin (TTM | estimate)
Gross
95.1%
EBITDA
34.2% | 237.0%
EBIT
32.3%
Net
35.1% | 27.6%
Free Cash Flow
34.8%
More
EPS
DKK17.7
FCF per Share
DKK17.8
Short interest
-
Employees
3k
Rev per Employee
DKK1.2m
Show more

Is Genmab A/S a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,019 stocks worldwide.

Genmab A/S Stock Analysis

Unlock Scores for Free

Analyst Opinions

29 Analysts have issued a Genmab A/S forecast:

21x Buy
72%
7x Hold
24%
1x Sell
3%

Analyst Opinions

29 Analysts have issued a Genmab A/S forecast:

Buy
72%
Hold
24%
Sell
3%

Financial data from Genmab A/S

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
3,231 3,231
25% 25%
100%
- Direct Costs 158 158
151% 151%
5%
3,074 3,074
22% 22%
95%
- Selling and Administrative Expenses 561 561
11% 11%
17%
- Research and Development Expense 1,437 1,437
21% 21%
44%
1,106 1,106
32% 32%
34%
- Depreciation and Amortization 63 63
384% 384%
2%
EBIT (Operating Income) EBIT 1,043 1,043
27% 27%
32%
Net Profit 1,134 1,134
44% 44%
35%

In millions DKK.

Don't miss a Thing! We will send you all news about Genmab A/S directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Genmab A/S operates as an international biotechnology company. The firm develops human antibody therapeutics for the treatment of cancer and other diseases. Its product pipeline include daratumumab, marketed as DARZALEX for the treatment of certain indications of multiple myeloma; teprotumumab-trbw marketed as TEPEZZA for the treatment of thyroid eye disease; and ofatumumab, marketed as Arzerra for the treatment of certain indications of chronic lymphocytic leukemia. The company was founded by Donald Lee Drakeman, Florian Schonharting, and Jan G. J. van de Winkel in 1999 and is headquartered in Copenhagen, Denmark.

Head office Denmark
CEO Jan Winkel
Employees 2,682
Founded 1998
Website www.genmab.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today